In pursuit of effective therapeutic agents for the ER-negative breast cancer, we previously demonstrated that bexarotene reduced mammary tumor development by 75% in ErbB2 mice. To further improve the effectiveness of breast cancer prevention, we have now investigated the effects of a combinatorial therapy consisting of two cancer preventive drugs. Based on the hypothesis, rexinoid LG100268 plus tamoxifen would more effectively prevent the development of both ER-positive and ER-negative breast cancer. We treated p53-null mammary gland mice with tamoxifen and LG100268 individually and in combination. By 60 weeks of age, vehicle treated mice developed tumors in 52% of transplanted mammary glands while mice treated with tamoxifen and LG100268 developed tumors in only 13% of transplanted mammary glands. To further define the mechanistic effects of this combinatorial treatment, we investigated the effects of tamoxifen and LG100268 on mammary tissue biomarkers. In mammary tissue harvested before tumor development, the proliferation markers Ki67 and cyclin D1 were significantly reduced in mice treated with the combination therapy. In addition, the rexinoid target genes ABCA1 and ABCG1 were induced in both the rexinoid and combination treatment groups, while expression remained constant in tamoxifen group. These results show that tamoxifen-LG100268 combinatorial treatment is more effective at preventing mammary tumors than either agent alone.
INTRODUCTION
Breast cancer is the second most common cause of cancer-related death in women in the United States [1] . Despite improvements in the early detection and treatment of breast cancer, its annual incidence rate in the U.S. comprises over 200,000 new cases and 40,000 deaths [2] . These data emphasize the importance of identifying effective preventive agents for breast cancer prevention.
Results from recent clinical trials have shown that anti-estrogens (including the selective estrogen receptor modulators (SERMs), tamoxifen and raloxifene) significantly prevent (≤50%) the development of ER-positive breast cancer [3] [4] [5] [6] [7] . However, these agents do not prevent the highly aggressive ER-negative breast cancers, which account for one-third of all breast cancer cases in the U.S. and carry poor prognoses [8] . Recently, several novel chemopreventive agents targeting non-endocrine signaling pathways have been tested in preclinical models. Of these, rexinoids (RXR specific retinoids) have been found to be the most effective agents for the prevention of ER-negative mammary tumors in animal models [9] [10] [11] .
We have previously shown that the RXR-selective retinoid bexarotene effectively suppresses ER-negative tumor development in MMTV-ErbB2 transgenic mice with minimal toxicity [11] .
Further studies showed that bexarotene also suppressed the development of preinvasive mammary lesions in MMTV-ErbB2 mice [12] . These data suggest that RXR-selective retinoids are promising agents for the prevention of ER-negative breast cancer. Bexarotene has also been shown to reduce mammary tumor development by 75% in p53 null mammary gland mice [13] .
Continuing our pursuit for more effective chemopreventive agents, we found that the rexinoid
LG100268 significantly reduces invasive mammary tumor development in MMTV-ErbB2 mice and that short-term treatment with LG100268 significantly prevents the development of preinvasive mammary lesions, including both hyperplasia and ductal carcinoma in situ [14] .
Although bexarotene appears to effectively prevent breast cancer, preclinical studies show multiple toxic effects to be associated with therapeutic application of this agent [15, 16] .
LG100268 on the other hand, is a more selective rexinoid and has been shown to significantly prevent ER-negative mammary tumor development with minimal toxicity [14] . These results suggest that the unilateral prevention of both ER-positive and ER-negative breast cancer may require a combination therapy relying on the individual preventive benefits obtained through treatment with both an anti-estrogen agent and a rexinoid. In this study, we investigate the effects of tamoxifen-LG100268 combinatorial treatment in the p53-null mammary tumor model. We hypothesize that the combination of tamoxifen with the rexinoid LG100268 will more effectively prevent the development of ER-positive and ER-negative breast cancers than either administered as a single-agent therapy. To test this hypothesis, we use a p53-null mammary gland mouse model that develops both ER-positive and ER-negative mammary tumors. Our results suggest that the combination of an anti-estrogen drug and a rexinoid should be considered for future studies in the prevention of both ER-positive and ER-negative breast cancer in high risk patients.
MATERIAL AND METHODS

Mice
All donor and recipient mice were bred and maintained at Baylor College of Medicine. The donor mice were Balb/c p53-null mammary gland, and the recipient mice were Balb/c p53-wild type [17] . All mice were maintained in a conventional mouse facility with room temperature set at 22°C, and food and water provided ad libitum. The animal facility is accredited by the 
Transplantation:
The basic transplantation protocol was previously described by Jerry and colleagues [17] . Briefly, 1-mm 2 fragments of mammary duct from 8-9-week-old female Balb/c p53-null mammary gland mice were transplanted into both cleared inguinal fat pads of 3-weekold Balb/c p53 wild type female mice. This procedure results in successful engraftment in over 90% of the recipient mice. The transplanted cells took 8wk to completely fill the mammary fat pads, therefore all treatments with chemopreventive agents started at 11wk of age to avoid any potential agent-induced effects on cellular capability to grow and fill the fat pads. In all transplantation experiments described, three different donors were used for each experiment with equal representation within the different groups. The doses of the two chemopreventive agents were chosen based on results from our previous study [14] , and were intentionally chosen to examine the effects of minimal, short exposure time (8-13 wk) doses of the two agents.
In animal experiment 1, there were three groups of mice comprised of 30-40 transplants in each group, with treatment occurring at 11-24wk of host age. Group A, representing the control mice, was implanted with a sham pellet; group B were given a tamoxifen pellet (5.0 mg); and group C were administered the rexinoid LG100268 (50mg/kg body weight) (5X/week).
Animal experiment 2 consisted of four groups of mice containing 30 to 34 transplants per group (Figure 2A ). Group A, consisting of control mice, was transplanted with sham pellet (11-19 wk) and fed cottonseed oil (21- LG100268 (50mg/kg body weight) by oral gavages (21-29 wk); and group D, the combined therapy group, were treated with a 2.5 mg tamoxifen pellet and were fed LG100268 (50mg/kg body weight). The mice were observed several times a week for any apparent signs of toxicity and were palpated weekly for tumors. All detected tumors were removed and fixed for histological sectioning upon reaching 5-10 mm in the maximal measurable diameter. Mice were sacrificed at 60 wk after transplantation, at which time any apparent mammary tumors were resected. At that time any remaining mammary gland tissue was processed for whole mount preparations.
In animal experiment 3 these same treatments were given to four groups of mice with slight modifications, i.e., the tamoxifen dose was increased from 2.5 to 5 mg. (see Figure 4 for treatment schema). Treatment times were for 13wk each and mammary fat pads were collected at 4hr after the last treatment in each group. Glands from each group were collected at the end of animal experiments 2 and 3 for whole mount preparations enabling the analysis of morphological development. In addition, epithelial cell pellets were prepared from animal experiment number 3 for use in the biomarker studies.
Mammary epithelial pellet preparation:
To prepare mammary epithelial cells from mouse mammary glands, the transplanted glands were harvested from euthanized mice, minced into small pieces, and digested with collagenase and hyaluronidase as previously described [18] .
Thoroughly digested tissue was centrifuged and washed in phosphate-buffered saline (PBS). Primer Express Software Version 2.0 software (Applied Biosystems, Foster City, CA). We used 6-carboxyfluorescein as the 5′ fluorescent reporter in combination with the 3′ Black Hole Quencher™ Double-Dye probe (Eurogentech, Seraing, Belgium). Standard curves for the quantification of each transcript and cyclophilin (used for normalization) were generated using a serially-diluted solution of synthetic templates. Genome equivalent copies were calculated from the standard curve and normalized to cyclophilin. The ratio between the values obtained provided relative gene expression levels. All reactions were performed in triplicate and statistical significance was determined by comparing the means of the triplicate samples using the Student's t-test.
Immunohistochemical analysis: Tumor samples were fixed in 4% paraformaldehyde then embedded in paraffin. Tissue sections were subsequently mounted on slides and processed for either Hematoxylin-eosin (H&E) staining or immunohistochemical (IHC) staining. H&E staining was conducted by deparaffinizing 4 μm tissue sections in xylene. Rehydration of sections in ethanol and water then took place, followed by 7 min incubation in hematoxylin.
Samples were destained in running water and fixed in acidified alcohol and ammonia. Finally, slides were incubated in eosin for 2 min, rinsed in alcohol and xylene, and mounted for evaluation. Red staining=ERα and blue staining =eosin.
For IHC studies, 4 μm tissue sections (from animal experiment 2) were mounted onto slides, which were deparaffinized. The endogenous peroxidase was blocked in 3% hydrogen peroxide buffer. Slides were subsequently rinsed in PBS, and nonspecific binding was blocked with 10% albumin. Samples were incubated with primary antibody anti-ERα (SC-542, 1:100, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), overnight at 4°C. This was followed by incubation with biotinylated anti-rabbit antibody (1:100) for 30 min. Peroxidase activity was visualized using the Vector NovaRED Substrate Kit (PK-6101, Vector Laboratories, Inc., Burlingame, CA) and the AEC Peroxidase Substrate Kit, 3-amino-9-ethylcarbazole (SK-4200, Vector Laboratories, Inc., Burlingame, CA). Finally, the slides were counterstained with hematoxylin for 30 sec and mounted with cover slips.
Statistical analysis: Tumor-free survival curves were estimated by the Kaplan-Meier method and statistically evaluated using the generalized Wilcoxon test. Every biomarker result is shown as the mean of three samples ± standard error. Significance was determined using a Student's ttest. Differences were considered statistically significant if the p-value < 0.05.
RESULTS
Tamoxifen-
LG100268 combined treatment inhibits development of mammary tumorigenesis in p53-null mice. Our previous studies indicated that the rexinoids bexarotene and LG100268 partially prevent the development of ER-negative breast cancer in MMTV-ErbB2 mice [9, 14] and in p53-null mammary gland mice [13] . To study the chemopreventive effects of a combination of the rexinoid LG100268 with tamoxifen, we chose the p53-null mammary gland mouse model which develops both ER-positive and ER-negative tumors due to a lack of tumor suppressor p53. Figure 1A shows the experimental schema for our first animal experiment. 
mammary glands at 60 wk post-transplantation (Figure 1B) , while mice treated with tamoxifen (5mg pellets) developed mammary tumors in 15% of the transplanted mammary glands and mice treated with the rexinoid LG100268 (50mg/kg body weight) developed mammary tumors in 8% of transplanted mammary glands (Figure 1B) .
In experiment 2, we strove to optimize the treatment regimen by lowering both the length of exposure time and dose of the drug. Figure 2A shows the experimental schema for this experiment. Group A mice were treated with a sham pellet and fed cottonseed oil, group B mice were treated with a tamoxifen pellet and fed cottonseed oil, group C mice were treated with a sham pellet and fed LG100268 (50mg/kg body weight) and group D mice were treated with a tamoxifen pellet and fed LG100268 (50mg/kg body weight). The results of sequential tamoxifen and rexinoid treatment on ER-positive and ER-negative mammary tumorigenesis in p53-null mice are shown in Figure 2B . Vehicle control mice treated with the sham pellet and rexinoid developed mammary tumors in 52% of the transplants at 60 weeks post-transplantation. On the other hand, mice treated with tamoxifen (2.5mg pellets) developed mammary tumors in 42% of the transplanted mammary glands, and mice treated with the rexinoid LG100268 developed tumors in 37% of the transplanted mammary glands. However, those mice exposed to tamoxifen and rexinoid LG100268 sequentially developed mammary tumors in only 13% of the transplanted mammary glands. This therapeutic combination provided a significant preventive effect of the agents given sequentially compared to either agent given alone (P=0.014).
Histopathologically, there were no discernible differences between tumors of the different treatment groups, and standard ductal carcinomas and carcinomas exhibiting a metaplastic histology were present in all groups. Figure 4A for the treatment schema). We analyzed the expression of 6 genes after 13 wk of treatment (as described in Methods). These included the proliferation marker Ki67, Trefoil factor 1 (TFF1; previously named pS2), the cell cycle marker cyclin D1, Adenosine triphosphate (ATP)-binding cassette transporter A1 (ABCA1), ATP-binding cassette, sub-family G member 1 (ABCG1), and insulin-like growth factor-binding protein 6 (IGFBP6). Treatment with tamoxifen alone or in combination with LG100268 resulted in a significant reduction in Ki67 levels; however treatment with rexinoid LG100268 alone produced no such result ( Figure 4B ). Cyclin D1 expression was reduced in mammary glands from mice treated with LG100268 alone or in combination with tamoxifen, but not in mice treated with tamoxifen alone (Figure 4C ). The expression of pS2, an ERα-regulated gene, was significantly reduced by treatment with the combination of tamoxifen and the rexinoid LG100268 ( Figure 5A ). The expression of the retinoid-regulated genes ABCA1 and ABCG1 [19, 20] as well as IGFBP6 [21] was significantly increased in the mammary glands from mice treated with either LG100268 alone or in combination with tamoxifen, but not in mice treated with tamoxifen alone (Figures 5B, 5C, 5D ).
In addition, we analyzed three mammary fat pads from each treatment group. While the control group showed normal ductal branching and lateral buds, those in the treatment group each had impaired ductal outgrowth. The rexinoid-treated group showed reduced size of ductal lumens, reduced branching and reduced lateral buds. The tamoxifen-alone group showed relatively normal ducts, but had drastically reduced lateral buds, and the combination tamoxifen-rexinoidtreated group showed greatly reduced size of ductal lumen, reduced branching, and virtually no lateral buds (Figure 6 ). 
DISCUSSION
The experiments presented here describe the effects of two chemopreventive agents, tamoxifen and the rexinoid LG100268, administered sequentially at low doses on mammary tumorigenesis in a genetically engineered p53-null mammary gland mouse model. The combination of tamoxifen and LG100268 was more effective in preventing mammary tumorigenesis than independent treatment with either agent. These results are of paramount importance in our continued pursuit of ways to effectively prevent breast cancer. The efficacy inherently associated with short-term (8 wk), low-dose treatment provides additional support for the combination chemoprevention strategy originally developed by Sporn and colleagues [22] . They showed that a combination of rexinoid LG100268 and selective ER modulators was more effective than either agent administered individually in two very different models: the chemical carcinogen-induced rat mammary tumor model and the MMTV-c-Neu mouse mammary tumor model. However, there are two key differences between the original protocol of Sporn and colleagues and the protocol we used in this study. First, we used a sequential exposure of the two agents, whereas Sporn and colleagues used a non-sequential combination of the two agents.
Second, we exposed recipient mice for a total of 16 wk, whereas they exposed recipient mice for 52-60 wk. Our experiments suggest that a relatively short exposure time is capable of providing an effective chemoprevention strategy. In addition, our results showing cancer preventive efficacy with low dose, short-term, sequential therapy indicates that these agents can be given for brief sequential periods to limit toxicity. is withdrawn, lesions develop with the same kinetics associated with untreated mice. In the rexinoid LG100268-treated mice, tumors develop in a biphasic manner, with normal kinetics (sharp slope) displayed in the early and late stages, divided by an alternative kinetic (shallow slope) in the mid-stages. These results can therefore be interpreted in terms of the stage of progression that is susceptible to the chemopreventive effects of the agents administered in this study. In the mouse mammary gland, tumors develop as a consequence of progression through several stages, from the well-defined preneoplastic stage to the invasive stage. Our results suggest that tamoxifen and LG100268 are more effective at preventing the development of preneoplasias than at preventing the progression of preneoplasias into invasive cancers. That interpretation is supported by earlier results that showed that the rexinoid bexarotene was not effective at preventing the progression of an existing p53-null preneoplastic outgrowth line to invasive cancer [13] at the same dose that greatly inhibited the development of mammary tumors in normal mammary cells exposed to the rexinoid. Additionally, experiments in which tamoxifen was given at early, middle, or late stages of progression for just four weeks showed the greatest preventive effect concomitant with administration of the agent early in tumor development (Medina, unpublished in breast cancer tissues [23] . We favor the interpretation that induction of transporter proteins like ABCA1 and ABCG1 exerts a preventive effect by an as yet undiscovered mechanism.
Our results indicate that low-dose tamoxifen followed by low-dose rexinoid is an effective chemopreventive regimen for preventing ER-positive and ER-negative mammary tumorigenesis with minimal toxicity. The preventive effect of tamoxifen-plus-LG100268 is primarily due to the suppression of mammary epithelial cell proliferation in the early stages of mammary tumorigenesis, suppressing the development of premalignant mammary lesions, and ultimately preventing the development of invasive breast cancer. Although LG100268 is quite effective in preventing ER-negative breast cancers in MMTV-ErbB2 mice [14] , chemoprevention with tamoxifen plus low-dose rexinoid LG100268, results in more effective prevention of the development of both ER-positive and ER-negative breast cancers in p53-null mammary glands.
These results support testing the combination of LG100268 and tamoxifen in other preclinical models of breast cancer. Such studies will support future breast cancer prevention trials testing combinations of rexinoids and anti-estrogen drugs.
Disclosure of Potential Conflicts of Interest
The authors have declared no conflicts of interest. 
